This round is no longer accepting investments, but hundreds just like it are live now.

Log In

GET A PIECE OF REVOLUTION MD

Reinventing Medication Delivery

Revolution MD has developed a solution to the opioid epidemic. Our patented Smart Inhaler combines biometric authentication with abuse deterrents in a proprietary blockchain network, for a real solution to prevent overdose and properly taper off medication as prescribed by physicians. Designed alongside healthcare providers and supported by a team of pharmaceutical and regulatory experts, we believe our portable device will make the opioid crisis a thing of the past, finally providing a solution to a problem that affects millions of Americans.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$58,210.47 Raised

REASONS TO INVEST

Opportunity to Invest in a Growing Biotech Market | The global biotechnology market stood at USD $627.63 Billion in 2020 and is expected to grow at a CAGR of 8.57% through 2026, while the global market for opioids was estimated at USD $25.4 Billion in 2020 and projected to reach US$31.9 Billion by 2027***

Revolution MD is supported by a world-class team of experts in pharmaceutical, regulatory, healthcare, cyber security, and finance industries, including Igor Gonda Pharma CEO, who successfully developed an opioid inhaler and navigated clinical trials.

Technology is Proven: 11 clinical trials have demonstrated the efficacy of inhaled opioids with fewer side effects

*Information provided by the Center for Disease Control and Prevention (source)

***Market statistics provided by Research and Markets (sourcesource)


*Images above are computer-generated renderings of the INHALE device. Product is currently under development.


The Problem



(source / source / source / source / source)

The Solution



*Images above are computer-generated renderings of the INHALE device. Product is currently under development.


The Market



(source / source / source / source)


Our Business Model



*Images above are computer-generated renderings of the INHALE device. Product is currently under development.


*Images above are computer-generated renderings of the INHALE device. Product is currently under development.


Why Invest



*Images above are computer-generated renderings of the INHALE device. Product is currently under development.


Replace
Drop image
(or click)

Loading image

ABOUT

HEADQUARTERS
5600 Crooked Pine Lane
Knoxville, TN 37921

Revolution MD has developed a solution to the opioid epidemic. Our patented Smart Inhaler combines biometric authentication with abuse deterrents in a proprietary blockchain network, for a real solution to prevent overdose and properly taper off medication as prescribed by physicians. Designed alongside healthcare providers and supported by a team of pharmaceutical and regulatory experts, we believe our portable device will make the opioid crisis a thing of the past, finally providing a solution to a problem that affects millions of Americans.

TEAM

Josh Kimmel
Josh Kimmel
President & Founder

Founder of BREATHE e-cigarette vaporizer Corporation (OTCQB BVAP,) and former CEO & President of 4M leading the commercialization of plasma oxidation for the production of carbon fiber at scale.

Ken Greenwood
Ken Greenwood
Chief Technology Officer

30 years SAP enterprise-scale implementations, ABAP, OO, SQL, XML, HTML et al, application performance, security, BI/BW big data, analytics and startup experience.

Mike Agentis
Mike Agentis
Chief Operating Officer

Business strategy, contract and project management, operation management, cost controls.

Jurgen Volrath

Jurgen Volrath

Chief Intellectual Property Officer

Former CIPO at SAP directly reporting to Hasso Plattner; co-founder of Corinthian Ophthalmic having developed and brought a vaporizer to market.

Garo Artinian

Garo Artinian

Advisory to Operations

Former CEO & Chairman of Draka Holding NV, a publicly listed company with revenue in excess of 3 billion Euro.

Igor Gonda

Igor Gonda

Chief Scientist

Former CEO of Aradigm Corporation. Lead strategic business alliances with major pharmaceutical and biotechnology companies. Research and development of products for major pharmaceutical markets such as diabetes and pain management. 

Don Treacy

Don Treacy

Clinical Development Manager

PH.D. Analytical Chemistry & CEO of the Magothy Group, inventor holding two patents: a pulsed dose drug delivery system and an antiviral agent.

Susan Clausen

Susan Clausen

Clinical Trials Manager

Clinical trials, clinical development, regulatory submissions, risk management, biotechnology, project management.

Richard Dapaah

Richard Dapaah

Venture Advisor

Venture Advisor with MBX Capital, a venture capital firm that funds high impact healthcare and life sciences strategy. Prior to MBX Capital, Richard was part of the founding team at Shire Capital Management, a global multi-strategy investment firm.

Paresh Chari

Paresh Chari

Advisor

Former Dura-Line Chairman of the Board & CEO, Advisory board for Wavin (Netherlands) and Netafim (Israel). Currently advisor to Onward Capital.

Bill Pittman

Bill Pittman

Advisor

Former President and COO of DeRoyal Industries. DeRoyal is a global manufacturer of over 3000 medical devices has over 3,000,000 ft under roof in 6 U.S. states and 7 countries. Annual revenue is approaching $1B.

TERMS

Revolution MD
Overview
PRICE PER SHARE
$2
DEADLINE
Jul 29, 2022
VALUATION
$26.71M
FUNDING GOAL
$10k - $1.07M
Breakdown
MIN INVESTMENT
$250
MAX INVESTMENT
$107,000
MIN NUMBER OF SHARES OFFERED
5,000
MAX NUMBER OF SHARES OFFERED
535,000
OFFERING TYPE
Equity
ASSET TYPE
Common Stock
SHARES OFFERED
Common Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares

*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.

Voting Rights of Securities Sold in this Offering

Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

Investment Incentives and Bonuses

Time-Based

Friends and Family Early Birds

Invest within the first 72 hours and receive 20% Bonus Shares.

Super Early Bird Bonus

Invest within the first week and receive 15% Bonus Shares.

Early Bird Bonus

Invest within the two weeks and receive 10% Bonus Shares.

Amount-Based

$1,000+ | Tier 1

Invest $1,000+ and receive 5% Bonus Shares.

$2,000+ | Tier 2

Invest $2,000+ and receive 10% Bonus Shares.

$5,000+ | Tier 3

Invest $5,000+ and receive 15% Bonus Shares.

$10,000+ | Tier 4

Invest $10,000+ and receive 20% Bonus Shares.

*All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

Revolution MD will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $2.00 / share, you will receive 110 Common Stock, meaning you'll own 110 shares for $200. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Any expense labeled “Travel and Entertainment”. Salary payments made to one’s self, a friend or relative.

PRESS

Article Image
Chicago News

REVOLUTION MD EXECUTES LETTER OF INTENT WITH FLAGSHIP CAPITAL FOR MULTI-MILLION DOLLAR INVESTMENT

Article Image
Teknovation

Revolution MD uses blockchain technology, IoT to dispense opioids more safely

ALL UPDATES

REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Revolution MD.

JOIN THE DISCUSSION

0/2500

KM
Kenneth Munson

a year ago

I get it. I like the idea. 1. Your Chief Science Advisor Igor Gonda held clinical trials up until stage 2b, why were the trials stopped? Why did it not go into stage 3? 2. What is the projected cost to produce? Are they reusable/refillable?

0

0

NP
Nikki Puiia

a year ago

Also, could you explain WHY and HOW prescription opioids are fueling the epidemic? I saw your source from 2015 about prescription abuse. What about the report released by the DEA in 2021 that says the diversion and abuse of opioid painkillers and other controlled prescription drugs (CPDs) are at their “lowest levels in nine years.”? Less than 1% of these pills are diverted. If it’s the lowest level in 9 years, how exactly is it fueling the current epidemic? Could you explain what exactly your product will fix? It sounds like you’re trying to fix a problem we had in 2015, not our current problem. If I could get an explanation on which problem we are facing in 2022 that you intend to fix, that would be really helpful. Here is the report I’m referring to. Thanks in advance! https://static1.squarespace.com/static/54d50ceee4b05797b34869cf/t/6056561b94da796fd4174ef0/1616270887543/DIR-008-21+2020+National+Drug+Threat+Assessment_WEB.pdf

2

0













NP
Nikki Puiia

a year ago

Do you have any sources from 2021-2022 or did you stop looking when they started disputing your “facts”? Could you tell us how many overdoses a day or even a year are caused by prescription pills ONLY. Not poly pharmacy? The vast majority of overdoses are caused by illegal street drugs. How does this product prevent that? Exactly how many overdoses would this product prevent when you don’t include street drugs in the equation? Our epidemic is a fentanyl and heroin epidemic. How will this product make even a small dent in this epidemic?

0

0

AB
Adam Beiter

2 years ago

Can you please answer my two previous questions. Not a good start for showing you're not like the rest of them.

1

0













AB
Adam Beiter

2 years ago

Will there be a Buprenorphine-naloxone one as well, Methadone has almost as bad a reputation as opiates?

3

0













AB
Adam Beiter

2 years ago

Smoking opiates is the second fastest way to get the drug in the system The faster the drug gets in your system the more euphoria, how will this reduce addiction?

2

0













MN
Michael Nadler

2 years ago

So this is essentially a blockchain based/smart contract ish pill bottle that dispenses the correct prescribed dose in the form of inhaling the "pill"? How about when you're on 2 pain medications at once- do you need to have 2 rev mds? Walk me through the logistics of this a little further- i.e. the doctor prescribes said opoid medication and then the patients goes to the pharmacy and picks up their pill bottle which is rev md and then rev md is using blockchain/smart technology to give the prescription to the patient accordingly? Lastly, what blockchain technology are you using- is it Ethereum or something else?

1

0













KT
Kirtson Thompson

2 years ago

A clear market need to bring greeter safety to the opioid dispensing market. A few questions: 1. Do you envision that every opioid prescription is fulfilled with your inhaler? 2. If so, what is your marketing strategy to fast track adoption (opioid manufacturer and pharmacy partnerships, etc)? 3. How long before you expect to have your FDA submission for review/approval? 4. What is your moat or barrier to entry by existing well funded big pharma? 5. What prevents a patient from bypassing the security of the inhaler to access the product?

3

0













HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

SECURE

Your info is your info. We take pride in keeping it that way!

DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

RAISED
$58,210.47
INVESTORS
81
MIN INVEST
$250
VALUATION
$26.71M

Get To Know Us

Our Team

Careers

Blog

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.

www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.
Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRASIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.
By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information

(800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.

StartEngine Marketplace

The availability of company information does not indicate that the company has endorsed, supports, or otherwise participates with StartEngine.

None of the information displayed on or downloadable from www.startengine.com (the 'Website') represents a recommendation, offer, or solicitation of an offer to buy or sell any security. It also does not constitute an offer to provide investment advice or service. StartEngine does not (1) make any recommendations or otherwise advise on the merits or advisability of a particular investment or transaction, or (2) assist in the determination of fair value of any security or investment, or (3) provide legal, tax, or transactional advisory services.

All investment opportunities are based on indicated interest from sellers and will need to be confirmed.

Investing in private company securities is not suitable for all investors. An investment in private company securities is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities. Each investment also carries its own specific risks, and you should complete your own independent due diligence regarding the investment. This includes obtaining additional information about the company, opinions, financial projections, and legal or other investment advice. Accordingly, investing in private company securities is appropriate only for those investors who can tolerate a high degree of risk and do not require a liquid investment.

StartEngine Marketplace (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC. StartEngine Bulletin Board ("SE BB") is a bulletin board platform that advertises interest in shares of private companies that previously executed Reg CF or Reg A offerings. SE BB enables shareholders to communicate interest in potential sales of shares in private companies and investors to discover, review, and potentially invest in private companies. As a bulletin board platform, SE BB provides a venue for investors to access information about private company offerings and connect with potential sellers. SE BB is distinct and separate from StartEngine Secondary (“SE Secondary”), which is an SEC-registered Alternative Trading System (ATS) operated by SE Primary. SE Secondary facilitates the trading of securities by matching orders between buyers and sellers and facilitating executions of trades on the platform. While a security may be displayed on the bulletin board, these securities will be subject to certain restrictions which may prevent the ability to buy and sell these securities in a timely manner, if at all. Even if a security is qualified to be displayed on the bulletin board, there is no guarantee an active trading market for the securities will ever develop, or if developed, be maintained. You should assume that you may not be able to liquidate your investment for some time or be able to pledge these shares as collateral.